YAbS








Step-by-Step Explanation:

How to browse the Results page

The Results page is divided in two sections.


  • The section at the top varies depending on which type of search has been performed. If the Advanced Search panel has been used, the top section will display pie charts and associated filtering boxes, to give a graphical overview of the filtered results in terms of general development status category, general molecular category, therapeutic area and target, and allow further filtering (as in the example below). If the Results page is displayed following a Quick Search, the top section will display pie charts and one associated filtering box, depending on the chosen type of search.
    1. To see the legend of each slice, hover over the pie chart slices.
    2. Pie charts can be expanded by clicking on the “Expand” button underneath each chart and exported in .png.

    Quick search options 40
  • The bottom section has a table showing detailed data for the filtered antibody entries. Each row represents an antibody entry and each column a variable with information regarding the molecule.
    Quick search options 41
    1. A bar shows how many pages there are, and which page is displayed, and allows you to select the page to display. The entries displayed and the total number of filtered entries are reported below the “Pages” bar.
      Quick search options 42
    2. You can choose the columns to display by clicking on the “Visible columns” dropdown menu located at the top left of the table and selecting the columns of interest. The whole table does not usually fit in the page and can be visualized by scrolling right.
    3. You can also select how many records per page to be displayed by using the “Show records” dropdown menu located on the top right of the table.
      Quick search options 43
    4. The table can be alphabetically sorted based on a certain column, by clicking on the column header.
      Quick search options 44
    5. The filtered records can be exported in .csv, and the exported table will include the data relative to all the columns in the dataset, regardless of which columns have been selected to be visible.
      Quick search options 45
    6. The Entry ID column displays the YAbS unique IDs for each molecule. You can view the dedicated page for each molecule by clicking on the molecule ID. You can use the go-back button of your browser to go back to the Results page.
      Quick search options 46

How to interpret a molecule dedicated page

Each molecule on the YAbS database has a unique ID shown in the Entry ID column on the Result page. You can access the dedicated page of a molecule by clicking on the ID. You can then use the browser back button to return to the Results page.
Quick search options 46
On the dedicated page, each molecule is described according to the dataset parameters grouped into:

  • Antibody information, including molecular characteristics and, when available, discovery method.
  • Therapeutic information, including target, primary therapeutic area, and indications.
  • Development stage information, including the most advanced stage of development and key dates of clinical development. In this section is also shown a bar chart providing a graphical overview of clinical development phase lengths. The phase lengths represented in the bar chart are calculated from the start of the first in human (FIH) study. You can see the phase lengths hovering on the bars in the bar chart. For all molecules, the early-stage clinical development phase lengths are provided, when applicable: Phase 1 length (FIH to start of Phase 2), and Phase 1+2 length (FIH to start of Phase 3). Some molecules start FIH study with a Phase 1/2, in this case, only Phase 1+2 length is provided. For molecules approved or evaluated for marketing authorization in the US, a complete overview of all clinical development phase lengths, including Phase 1+2+3 length (FIH to Date BLA/NDA submitted) and Phase 1 to US approval length (FIH to Date of first US approval) is provided.
  • Company information, including development timelines, information on specific clinical trials, regulatory agency designations, and company acquisitions and collaborations.
  • Approval information, and
  • Location of the company developing the molecule.

How to export data

  • Export the whole dataset

    The quickest way to export all records is to select any of the Quick Search options from the Database homepage, and, once taken on the Results page, simply click on the "Export table" button located on the top left of the results table.
    By clicking on the "Export table" button the filtered records will be exported in .csv, and the exported table will include the data relative to all the columns in the dataset, regardless of which columns have been selected to be visible.

  • Export the filtered results

    Once you perform the search and filtering, you will be taken to a Results page. In the table section of the Results page, located on the top left of the table, there is an "Export table" button.
    By clicking on the "Export table" button the filtered records will be exported in .csv, and the exported table will include the data relative to all the columns in the dataset, regardless of which columns have been selected to be visible.


    Quick search options 45

YAbS Database Variable Definitions

This table provides detailed definitions for the variables used in the YAbS database. Each variable is described along with its significance, categorization, and any additional information relevant to its use in the database.


Variable Definition
Record category Top-level status of current development.
  1. Approved: Currently approved as a therapeutic agent and marketed in at least one country.
  2. Withdrawn: Product was approved by at least one regulatory agency, but subsequently removed from all markets.
  3. Regulatory review: The first marketing application was submitted to a regulatory agency in any country.
  4. Clinical: Currently undergoing evaluation in humans as an investigational drug.
  5. No development reported: No development activity has been reported within the past ~2-3 years.
  6. Terminated: Asset has been administered to humans, but all clinical development by any company has ceased.
  7. IND: Asset for which an application to initiate clinical studies has been submitted, but the studies have not yet started.
  8. Preclinical: Asset is in preclinical development; focus in on molecules that may enter clinical study within 1-2 years.
Number Unique database identification number.
Status check Most recent date that data for the record was added or updated.
INN International non-proprietary name assigned by the World Health Organization.
Drug code(s) Codes assigned by any company involved in the development of the molecule.
Brand name Name used for marketing an approved product.
mAb sequence source Indicates whether the mAb is human, humanized, chimeric, murine, or a combination of these. TBD = to be determined. When the category is separated by a back slash (/) the information refers to variable domains on the same molecule. When the category is separated by a comma, the information refers to different components of a mixture.
General Molecular Category Top-level category or categories of the molecule, such as naked monospecific, antibody-drug conjugate, bispecific, immunoconjugate, mixture, radio-immunotherapy. One molecule can be labelled with multiple molecular categories. A detailed overview of the general molecular category classification strategy is shown in Supplemental Figure S1.
Format, general category Top-level category for the antibody format, such as full length, appended Ig, fragment, fragment-Fc. If the molecule is not naked, the format is followed by “conjugate” or “fusion” as appropriate. TBD = to be determined. A detailed overview of the format classification strategy is shown in Supplemental Figure S2.
Format details Additional details for format, when known. The details are separated by commas and ordered from broad to fine detail. Format synonyms are listed in alphabetical order. A detailed overview of the format classification strategy is shown in Supplemental Figure S3. TBD = to be determined.
Target(s) Antigen or antigens targeted by the antibody. The target(s) for the antibody portion of the molecule are first, in the order: target(s) on tumor/non-immune-cell, in alphabetical order; target(s) on immune cell, in alphabetical order; followed by cytokine/chemokines targets, in alphabetical order; and, for molecules fused non-antibody protein domains categorized as receptors, the target for the fused receptor, if any are known.
Isotype (Fc) If the molecule has an Fc domain, indicates the immunoglobulin isotype, if known. TBD = to be determined.
Light chain isotype If the molecule has a light chain, indicates the light chain isotype: kappa, lambda, or a combination of these, if known.
Linker Indicates the type of linker used in antibody-payload conjugation.
Ave. DAR Drug-to-antibody ratio for antibody-drug conjugates.
Conjugated/fused moiety Indicates the general type of molecule conjugated or protein fused to the antibody portion of antibody-drug conjugates, radioimmunoconjugates (RIC), or immunoconjugates (e.g. tubulin inhibitor, DNA binding, Topoisomerase I inhibitor, Isotope, Chelator, Polymer, Receptor, Enzyme, Oligonucleotide, etc.), followed by the detail of the specific molecule conjugated or protein fused.
Description/comment Further details about the molecule and links to relevant data sources.
Discovery method/technology Indicated the method or technology used to create the molecule, such as hybridoma, human B-cell derived, transgenic mouse, phage or yeast display, if known.
Anticipated events Indicated forecasted events, such as investigational new drug application filing or marketing application submission, or planned or pending clinical studies.
Most advanced stage of development (global) Detailed data for the current status of the molecule, such as most advanced phase of clinical development in any country, top countries of approval or regulatory review (e.g., EU, US, Japan, China), highest phase when terminated.
Status Indicates top-level status, such as active, no development reported, inactive.
Start of clinical phase Indicates the earliest known date for entry into clinical study, which may be either an investigational new drug application filing in any country or a first-in-human study start date. Date may be for a Phase 1/2 study if no Phase 1 study was done.
Start of first Phase 2 Indicates the start date for the first Phase 2 study in any indication. Date may be for a Phase 1/2 study if a Phase 1 study was previously completed.
Start of first Phase 3 Indicates the start date for the first Phase 3 study in any indication. The date may be for the start of a Phase 2/3 study if a Phase 3 study was not previously started.
Indications of clinical studies Diseases for which the antibody was evaluated as a treatment. Indications are entered in chronological order as the studies are started, i.e., the most recent unique indication will appear first in the list.
Primary therapeutic area Therapeutic area of the majority of clinical studies of the investigational antibody therapeutic.
Company Company that originated the molecule, if known, or the company conducting clinical development.
Licensee/Partner Company that licensed the molecule or a development partner of the company conducting clinical development.
Comments about company or candidate Notable events that occurred during the development of the molecule. Data is entered in chronological order, i.e., the most recent event will appear first.
Factor(s) contributing to discontinuation Reasons for termination, if known, such as safety, lack of efficacy, business decision.
Year of first approval (global) Year the product was first approved in any country.
Date BLA/NDA submitted to FDA Date the first marketing application was submitted to the US Food and Drug Administration.
Date of first US approval Date of the first approval by the US Food and Drug Administration.
INN, US product name International non-proprietary name assigned by the World Health Organization and the non-proprietary name assigned by the US Food and Drug Administration.
US or EU first approved indications Indication first approved by the Food and Drug Administration or European Commission; may also include indications of supplemental approvals.
Full address of company Postal address of the company that originated or is developing the molecule.
Country of the company Country in which the headquarters of the company that originated or is developing the molecule is located.
Region of country Region where the headquarters of the company that originated or is developing the molecule is located.
Company website URL of the company website.

General Molecular Classification System

To describe antibody general molecular category, we considered five possible features that can describe the molecule: 1) specificity, 2) conjugation status, 3) one molecule or mixture drug composition, 4) mechanism of action (MOA), 5) antigen binding properties. White boxes represent entries composed of one standard Y shaped, monospecific, naked antibody molecule, with canonical MOA (blocking, agonist, antigen clearance, cell mediated effector function, payload delivery) and canonical antigen binding properties. Blue boxes represent the broad variables displayed in the “General molecular category” category. Green boxes represent additional variables that describe the molecule in detail. Grey boxes are represented in the schematic to better describe immunoconjugates, but are not displayed in the database. Unless stated otherwise with the variables described in the blue and green boxes, we assume the molecule is canonical and described by terms in the white boxes. Each molecule can be described by one or more of the above described variables.


Detail 1


General Format Classification System

The schematic represents the rationale behind our standardization method to describe the general format of therapeutic antibodies. We first divided them in two groups: naked antibodies and antibodies that are chemically conjugated or fused to a non-immunoglobulin derived molecule. We further divided naked antibodies into four categories as described in the schematic: Full length Ab, Appended IgG, Fragment, Fragment Fc. Each of these categories can also be conjugated or fused to one or more non-immunoglobulin derived molecules, as shown on the schematic. Blue boxes represent the variables represented in the database. Only one variable can be assigned to a molecule.


Detail 2


Detailed Format Classification System

The schematic represents the rationale behind the additional information we provide on the format. When available, we provide information on the type of format (e.g. type of fragment, type of fragment-Fc, type of fragment-Ig) and proprietary name. For bispecific antibodies, when available and if applicable, we also provide information of valency, symmetry, and heterodimerization and light chain pairing strategies.


Detail 3

The Tutorial videos from The Antibody Society will be uploaded here and in all major social media platforms.